Literature DB >> 18690541

Self-built supercritical CO2 anti-solvent unit design, construction and operation using carbamazepine.

Dan Meng1, James Falconer, Karen Krauel-Goellner, John J J J Chen, Mohammed Farid, Raid G Alany.   

Abstract

The purpose of this study was to design and build a supercritical CO(2) anti-solvent (SAS) unit and use it to produce microparticles of the class II drug carbamazepine. The operation conditions of the constructed unit affected the carbamazepine yield. Optimal conditions were: organic solution flow rate of 0.15 mL/min, CO(2) flow rate of 7.5 mL/min, pressure of 4,200 psi, over 3,000 s and at 33 degrees C. The drug solid-state characteristics, morphology and size distribution were examined before and after processing using X-ray powder diffraction and differential scanning calorimetry, scanning electron microscopy and laser diffraction particle size analysis, respectively. The in vitro dissolution of the treated particles was investigated and compared to that of untreated particles. Results revealed a change in the crystalline structure of carbamazepine with different polymorphs co-existing under various operation conditions. Scanning electron micrographs showed a change in the crystalline habit from the prismatic into bundled whiskers, fibers and filaments. The volume weighted diameter was reduced from 209 to 29 mum. Furthermore, the SAS CO(2) process yielded particles with significantly improved in vitro dissolution. Further research is needed to optimize the operation conditions of the self-built unit to maximize the production yield and produce a uniform polymorphic form of carbamazepine.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18690541      PMCID: PMC2977050          DOI: 10.1208/s12249-008-9130-0

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  15 in total

Review 1.  Phase behavioral effects on particle formation processes using supercritical fluids.

Authors:  S Palakodaty; P York
Journal:  Pharm Res       Date:  1999-07       Impact factor: 4.200

2.  What is the true solubility advantage for amorphous pharmaceuticals?

Authors:  B C Hancock; M Parks
Journal:  Pharm Res       Date:  2000-04       Impact factor: 4.200

3.  Rapid expansion from supercritical to aqueous solution to produce submicron suspensions of water-insoluble drugs.

Authors:  T J Young; S Mawson; K P Johnston; I B Henriksen; G W Pace; A K Mishra
Journal:  Biotechnol Prog       Date:  2000 May-Jun

4.  Study of the solid state of carbamazepine after processing with gas anti-solvent technique.

Authors:  M Moneghini; I Kikic; D Voinovich; B Perissutti; P Alessi; A Cortesi; F Princivalle; D Solinas
Journal:  Eur J Pharm Biopharm       Date:  2003-09       Impact factor: 5.571

Review 5.  Stabilization of proteins in dry powder formulations using supercritical fluid technology.

Authors:  Natasa Jovanović; Andréanne Bouchard; Gerard W Hofland; Geert-Jan Witkamp; Daan J A Crommelin; Wim Jiskoot
Journal:  Pharm Res       Date:  2004-11       Impact factor: 4.200

6.  Processing of carbamazepine-PEG 4000 solid dispersions with supercritical carbon dioxide: preparation, characterisation, and in vitro dissolution.

Authors:  M Moneghini; I Kikic; D Voinovich; B Perissutti; J Filipović-Grcić
Journal:  Int J Pharm       Date:  2001-07-03       Impact factor: 5.875

7.  Formation of phenytoin nanoparticles using rapid expansion of supercritical solution with solid cosolvent (RESS-SC) process.

Authors:  Ranjit Thakur; Ram B Gupta
Journal:  Int J Pharm       Date:  2005-12-13       Impact factor: 5.875

8.  Crystallization of pure anhydrous polymorphs of carbamazepine by solution enhanced dispersion with supercritical fluids (SEDS).

Authors:  A D Edwards; B Y Shekunov; A Kordikowski; R T Forbes; P York
Journal:  J Pharm Sci       Date:  2001-08       Impact factor: 3.534

9.  Solubility and conversion of carbamazepine polymorphs in supercritical carbon dioxide.

Authors:  R Bettini; L Bonassi; V Castoro; A Rossi; L Zema; A Gazzaniga; F Giordano
Journal:  Eur J Pharm Sci       Date:  2001-06       Impact factor: 4.384

10.  Polymorphic properties of micronized carbamazepine produced by RESS.

Authors:  P M Gosselin; R Thibert; M Preda; J N McMullen
Journal:  Int J Pharm       Date:  2003-02-18       Impact factor: 5.875

View more
  1 in total

1.  The effects of supercritical carbon dioxide processing on progesterone dispersion systems: a multivariate study.

Authors:  James R Falconer; Jingyuan Wen; Sara Zargar-Shoshtari; John J Chen; Farid Mohammed; Judy Chan; Raid G Alany
Journal:  AAPS PharmSciTech       Date:  2012-09-20       Impact factor: 3.246

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.